Replies to post #121754 on Biotech Values

[jq1234]

Based on this data and the overall clinical profile of CXA-201, the company will be engaging global regulatory authorities to discuss a CXA-201 nosocomial pneumonia Phase 3 study design and expects to begin Phase 3 studies in this indication in 2012.

It's interesting CBST is committed to start phase III for CXA201, but not CB-183,315.

From Biocentury:

Cubist plans to announce a formal decision on whether to start Phase III testing with CB-183,315 by year end.